M&A Deal Summary

EyePoint Pharmaceuticals Acquires Icon Bioscience

On March 28, 2018, EyePoint Pharmaceuticals acquired life science company Icon Bioscience for 61M USD

Acquisition Highlights
  • This is EyePoint Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is EyePoint Pharmaceuticals’ largest (disclosed) transaction.
  • This is EyePoint Pharmaceuticals’ 1st transaction in the United States.
  • This is EyePoint Pharmaceuticals’ 1st transaction in California.

M&A Deal Summary
Date 2018-03-28
Target Icon Bioscience
Sector Life Science
Buyer(s) EyePoint Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 61M USD

Target

Icon Bioscience

Newark, California, United States
Icon Bioscience, Inc. is a specialty biopharmaceutical company focused on the development and commercialization of unique ophthalmic pharmaceuticals based on its patented and proprietary Verisome® extended-release drug delivery technology. Icon Bioscience is based in Newark, California.

Search 200,577 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

EyePoint Pharmaceuticals

Watertown, Massachusetts, United States
Category Company
Founded 1987
Sector Medical Products
Employees121
Revenue 46M USD (2023)
DESCRIPTION

EyePoint Pharmaceuticals is a provider of miniaturized, sustained-release drug delivery products and is continuing the evolution of these systems. EyePoint Pharmaceuticals was incorporated in 1987 and is based in Watertown, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2018) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal